Holen Sie sich die Stockscreener-App
0.672
8.45%
-0.062
Handel nachbörslich:
.70
0.028
+4.17%
Schlusskurs vom Vortag:
$0.734
Offen:
$0.74
24-Stunden-Volumen:
275.98K
Relative Volume:
0.11
Marktkapitalisierung:
$3.83M
Einnahmen:
$34.07M
Nettoeinkommen (Verlust:
$-20.13M
KGV:
-0.0393
EPS:
-17.1162
Netto-Cashflow:
$-24.90M
1W Leistung:
-18.05%
1M Leistung:
-20.00%
6M Leistung:
-37.20%
1J Leistung:
-81.44%
1-Tages-Spanne:
$0.6513
$0.7599
1-Wochen-Bereich:
$0.6513
$1.0099
52-Wochen-Spanne:
$0.61
$4.04
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Vergleichen Sie BFRI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BFRI | 0.672 | 3.83M | 34.07M | -20.13M | -24.90M | -17.12 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey
Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com
Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire
Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance
Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia
Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India
Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Mass. Biotech Receives FDA Approval - Streetwise Reports
Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa
Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India
What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News
Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks
FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times
FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan
BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biotech Stocks Facing FDA Decision In October 2024 - RTTNews
Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance
Five PDUFA dates on FDA’s October agenda - BioCentury
Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan
Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News
Trading Day Triumph: Biofrontera Inc (BFRI) Ends at 1.28, a 0.00 Surge/Plunge - The Dwinnex
A stock that deserves closer examination: Biofrontera Inc (BFRI) - US Post News
Leidos Holdings, Inc. (NYSE:LDOS) Shares Sold by Tredje AP fonden - Defense World
Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex
Taking the lead: Biofrontera Inc (BFRI) - SETE News
Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):